Suppr超能文献

吸烟者肺气肿和小气道疾病的进展

Progression of Emphysema and Small Airways Disease in Cigarette Smokers.

作者信息

Pompe Esther, Moore Camille M, Mohamed Hoesein Firdaus A A, de Jong Pim A, Charbonnier Jean-Paul, Han MeiLan K, Humphries Steven M, Hatt Charles R, Galbán Craig J, Silverman Ed K, Crapo James D, Washko George R, Regan Elisabeth A, Make Barry, Strand Matthew, Lammers Jan-Willem J, van Rikxoort Eva M, Lynch David A

机构信息

Imaging Department, University Medical Center Utrecht, Utrecht, the Netherlands.

Division of Biostatistics, Environment and Health, National Jewish Health, Denver, Colorado, United States.

出版信息

Chronic Obstr Pulm Dis. 2021 Apr 27;8(2):198-212. doi: 10.15326/jcopdf.2020.0140.

Abstract

BACKGROUND

Little is known about factors associated with emphysema progression in cigarette smokers. We evaluated factors associated with change in emphysema and forced expiratory volume in 1 second (FEV) in participants with and without chronic obstructive pulmonary disease (COPD).

METHODS

This retrospective study included individuals participating in the COPD Genetic Epidemiology study who completed the 5-year follow-up, including inspiratory and expiratory computed tomography (CT) and spirometry. All paired CT scans were analyzed using micro-mapping, which classifies individual voxels as emphysema or functional small airway disease (fSAD). Presence and progression of emphysema and FEV were determined based on comparison to nonsmoker values. Logistic regression analyses were used to identify clinical parameters associated with disease progression.

RESULTS

A total of 3088 participants were included with a mean ± SD age of 60.7±8.9 years, including 72 nonsmokers. In all Global initiative for chronic Obstructive Lung Disease (GOLD) stages, the presence of emphysema at baseline was associated with emphysema progression (odds ratio [OR]: GOLD 0: 4.32; preserved ratio-impaired spirometry [PRISm]; 5.73; GOLD 1: 5.16; GOLD 2: 5.69; GOLD 3/4: 5.55; all ≤0.01). If there was no emphysema at baseline, the amount of fSAD at baseline was associated with emphysema progression (OR for 1% increase: GOLD 0: 1.06; PRISm: 1.20; GOLD 1: 1.7; GOLD 3/4: 1.08; all ≤ 0.03).In 1735 participants without spirometric COPD, progression in emphysema occurred in 105 (6.1%) participants and only 21 (1.2%) had progression in both emphysema and FEV.

CONCLUSIONS

The presence of emphysema is an important predictor of emphysema progression. In patients without emphysema, fSAD is associated with the development of emphysema. In participants without spirometric COPD, emphysema progression occurred independently of FEV decline.

摘要

背景

关于吸烟者肺气肿进展的相关因素知之甚少。我们评估了慢性阻塞性肺疾病(COPD)患者和非COPD患者中与肺气肿变化及第一秒用力呼气容积(FEV)相关的因素。

方法

这项回顾性研究纳入了参与COPD遗传流行病学研究并完成5年随访的个体,包括吸气和呼气计算机断层扫描(CT)及肺功能测定。所有配对的CT扫描均使用微映射进行分析,该方法将各个体素分类为肺气肿或功能性小气道疾病(fSAD)。根据与非吸烟者值的比较确定肺气肿和FEV的存在及进展情况。采用逻辑回归分析来确定与疾病进展相关的临床参数。

结果

总共纳入了3088名参与者,平均年龄±标准差为60.7±8.9岁,其中包括72名非吸烟者。在所有慢性阻塞性肺疾病全球倡议(GOLD)阶段,基线时肺气肿的存在与肺气肿进展相关(优势比[OR]:GOLD 0期:4.32;肺功能正常-肺量计异常[PRISm]:5.73;GOLD 1期:5.16;GOLD 2期:5.69;GOLD 3/4期:5.55;均≤0.01)。如果基线时没有肺气肿,基线时fSAD的量与肺气肿进展相关(每增加1%的OR:GOLD 0期:1.06;PRISm:1.20;GOLD 1期:1.7;GOLD 3/4期:1.08;均≤0.03)。在1735名无肺功能测定COPD的参与者中,105名(6.1%)出现了肺气肿进展,只有21名(1.2%)肺气肿和FEV均有进展。

结论

肺气肿的存在是肺气肿进展的重要预测指标。在无肺气肿的患者中,fSAD与肺气肿的发生相关。在无肺功能测定COPD的参与者中,肺气肿进展独立于FEV下降而发生。

相似文献

1
Progression of Emphysema and Small Airways Disease in Cigarette Smokers.吸烟者肺气肿和小气道疾病的进展
Chronic Obstr Pulm Dis. 2021 Apr 27;8(2):198-212. doi: 10.15326/jcopdf.2020.0140.

引用本文的文献

本文引用的文献

10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验